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Introduction: Human adipose tissue-derived stem cells (hASCs) are attractive cells for therapeutic applications and
are currently being evaluated in multiple clinical trials. Prior to their clinical application, hASCs must be expanded
ex vivo to obtain the required number of cells for transplantation. Fetal bovine serum is the supplement most
widely used for cell culture, but it has disadvantages and it is not safe for cell therapy due to the risks of pathogen
transmission and immune reaction. Furthermore, the cell expansion poses a risk of accumulating genetic abnormalities
that could lead to malignant cell transformation. In this study, our aim was to evaluate the proliferation pattern as well
as the resistance to spontaneous transformation of hASCs during expansion in a xeno-free culture condition.
Methods: hASCs were expanded in Dulbecco’s modified Eagle’s medium supplemented with pooled allogeneic
human serum or fetal bovine serum to enable a side-by-side comparison. Cell viability and differentiation capacity
toward the mesenchymal lineages were assessed, along with immunophenotype. Ki-67 expression and the proliferation
kinetics were investigated. The expression of the transcription factors c-FOS and c-MYC was examined with Western
blot, and MYC, CDKN2A, ERBB2 and TERT gene expression was assessed with quantitative PCR. Senescence was
evaluated by β-gal staining. Karyotype analysis was performed and tumorigenesis assay in vivo was also evaluated.
Results: The hASCs expanded in medium with pooled allogeneic human serum did not show remarkable differences
in morphology, viability, differentiation capacity or immunophenotype. The main difference observed was a
significantly higher proliferative effect on hASCs cultured in pooled allogeneic human serum. There was no significant
difference in C-FOS expression; however, C-MYC protein expression was enhanced in pooled allogeneic human serum
cultures compared to fetal bovine serum cultures. No difference was observed in MYC and TERT mRNA levels. Moreover,
the hASCs presented normal karyotype undergoing senescence, and did not form in vivo tumors, eliminating the
possibility that spontaneous immortalization of hASCs had occurred with pooled allogeneic human serum.
Conclusions: This complete characterization of hASCs cultivated in pooled allogeneic human serum, a suitable
xeno-free approach, shows that pooled allogeneic human serum provides a high proliferation rate, which can be
attributed for the first time to C-MYC protein expression, and showed cell stability for safe clinical applications in
compliance with good manufacturing practice.* Correspondence: goes@icb.ufmg.br
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Mesenchymal stem cells (MSCs) are fibroblast-like cells
with intrinsic characteristics of self-renewal, long-term
viability, multilineage differentiation capacity into cells
of mesodermal origin (such as osteoblasts, chondrocytes,
and adipocytes), and possibly to cells of nonmesodermal
origin (the ectodermal [1] and endodermal lineages [2]),
hypoimmunogenic, and immunosuppressive properties
[3-5]. Studies suggest that MSCs can regenerate tissues
by two different mechanisms: (1) the cells can differenti-
ate along a specific lineage pathway, thus replacing the
damaged tissue; and (2) through the paracrine release of
trophic factors to induce tissue repair by endogenous
cells [6]. MSCs can be derived from a variety of adult tis-
sues (for example, bone marrow [7], amniotic fluid [8],
adipose tissue [5], dental pulp [9], and so forth). Adipose
tissue is a rich and very convenient source of MSCs,
usually termed human adipose tissue-derived stem cells
(hASCs), which in culture retain markers in common
with the other MSCs [10]. The use of hASCs for thera-
peutic applications has grown substantially in the last
years, because the use of stem cells from adult tissues
circumvent some ethical issues associated with the appli-
cation of embryonic stem cells, and because of their ac-
cessibility via isolation from lipoaspirates, a disposable
byproduct of cosmetic surgery.
Multiple clinical trials are underway to evaluate the
use of hASCs in several fields of regenerative medicine
[6,11-14]. However, before hASCs can be used in clinical
applications, it is necessary to expand these cells ex vivo
in compliance with current good manufacturing practice
(GMP) guidelines to acquire the required number of
cells [6,15]. Moreover, quality control assessments must
be carried out at all phases of cell manipulation, includ-
ing functional assays, sterility control [16], and tests to
ensure that spontaneous malignant cell transformation
has not occurred [6,15,17].
For the successful cultivation of stem cells for therap-
ies, appropriate culture conditions that mimic the
physiological conditions in vivo and in situ are required.
hASCs are often expanded in classical culture media,
such as minimum essential medium, Dulbecco’s modi-
fied Eagle’s medium, RPMI-1640 and DMEM:F12, com-
monly supplemented with fetal bovine serum (FBS) that
serves to provide hormones, proteins, minerals, and
several other factors [18]. However, the use of animal-
derived components in human cell culture has disadvan-
tages, including the potential for immune reactions [19],
the presence of xenogeneic proteins that are internalized
or attached on surfaces of cells [20-22], and the possibil-
ity of infectious agent transmission [23,24]. Thus, FBS is
not a suitable option for patient safety, and novel
approaches are being developed to substitute FBS with al-
ternatives such as human AB serum [25-29], thrombin-activated platelet-rich plasma [26,27], platelet-lysate
[26,30] and chemically defined medium [31-35].
Concerns that human MSCs may be prone to malig-
nant transformation have been recently raised. In fact,
murine bone marrow-derived stem cells have been
shown to undergo spontaneous transformation after
long-term in vitro culture [36]. On the contrary,
Bernardo and colleagues [37] showed that human bone
marrow-derived stem cells do not display an aptitude for
spontaneous transformation. Murine MSCs may be
particularly predisposed to spontaneous transformation
because there are many differences with regard to mech-
anisms of transformation in human and mouse cells
[38,39]. It is likely that this is due to different genetic/
epigenetic control of the genome in the two species.
These controversies about the stability of human MSCs
highlight the necessity to investigate carefully the stability
of human MSCs in long-term cultures before clinical use.
Developing the ideal culture medium remains an im-
portant challenge. Recently our group substituted FBS
with pooled allogeneic human serum (aHS) to supple-
ment the basal medium for human MSCs cultures
[40,41] which provided suitable conditions to expand
these cells in vitro with an increased proliferation pat-
tern. Thus, our aim in this study was to evaluate the
proliferation pattern as well as the resistance to spontan-
eous transformation of these hASCs during in vitro ex-
pansion in this proposed xeno-free culture condition.
Through this complete characterization of hASCs cul-
tured in medium supplemented with aHS, we observed
that aHS provides a high proliferation rate compared
with the FBS supplementation, which was attributed for
the first time to higher c-MYC protein expression in
aHS cultures. Additionally it was shown that hASCs
maintain their phenotypic, functional and genetic stabil-
ity without any evidence of cell transformation.
Materials and methods
Pooled allogeneic human serum
aHS was obtained from the whole blood of distinct
blood-group-typed donors, as previously described by
our group [40]. Donors gave written informed consent
according to the approval of this study by the Ethics
Committee in Research of the Universidade Federal de
Minas Gerais (n° ETIC 11668613.7.0000.5149), advisory
board of National Health Council (CNS). No clinical or
laboratory evidence of metabolic diseases, hepatitis, HIV,
or other systemic complications was observed for the
donors. Briefly, the blood was collected from each donor
using vacutainer tubes (Biosciences, USA) and allowed
to clot spontaneously at 4°C. The serum was separated
by centrifugation at 252 g at 4°C for 15 minutes. Differ-
ent blood types (A, B, AB and O) from 20 (five of each
blood type) different donors were mixed to produce the
Paula et al. Stem Cell Research & Therapy  (2015) 6:76 Page 3 of 19batches of aHS. The aHS was inactivated at 56°C for
30 minutes prior to use and kept frozen at −20°C. The
batches of aHS were used in the culture of all hASCs
studied in this work.
Culture media
Basal medium consisted of Dulbecco’s modified Eagle’s
medium-high glucose (Sigma-Aldrich, USA) supplemented
with 5 mM sodium bicarbonate (Cinética Química Ltda,
Brazil), penicillin (100 units/mL; Sigma-Aldrich), strepto-
mycin (0.1 mg/mL; Sigma-Aldrich), amphotericyn B
(0.25 μg/mL; Sigma-Aldrich), gentamicin (60 mg/L;
Schering-Plough, USA), and 10% of either aHS or FBS
(Cripion Biotecnologia Ltda, Brazil). Adipogenic medium
consisted of basal medium with 0.5 mM isobutylmethyl-
xanthine (Sigma-Aldrich), 200 μM indomethacin (Sigma-
Aldrich), 1 μM dexamethasone (Aché, Brazil), and 10 μM
insulin (Eli Lilly and Company, USA). Osteogenic medium
consisted of basal medium with 50 μg/mL ascorbate-2-
phosphate (Ecibra, Brazil), 10 mM β-glycerophosphate
(Sigma-Aldrich), and 0.1 μM dexamethasone (Aché).
Chondrogenic medium consisted of basal medium with
1 mM dexamethasone (Aché), 125 μg/mL bovine serum
albumin (PAA, Austria), 1 mM pyruvate (Sigma-Al-
drich), 200 U/mL insulin (Eli Lilly and Company),
3.25 μg/mL transferrin (Wako, Brazil), 0.01 μg/mL trans-
forming growth factor-β1 (Sigma-Aldrich), 5 mg/mL
ascorbate-2-phosphate (Ecibra) and a reduced concentra-
tion of serum supplements - 1% aHS or 1% FBS [5].
Isolation and culture of human adipose tissue-derived
stem cells
Human adipose tissue was harvested from healthy patients
who had abdominal reduction surgery for aesthetic reasons
at Núcleo de Cirurgia Plástica, Belo Horizonte, Minas Ger-
ais, Brazil. No metabolic diseases, HIV, hepatitis, or other
systemic complications were reported from these patients.
The Núcleo de Cirurgia Plástica supplied the information
about ABO blood and Rh group of lipoaspirate donors
(data not shown). Lipoaspirate from 10 different donors,
ranging in age from 20 to 40 years, were assessed in this
study. The patients gave written informed consent accord-
ing to the approval of this study by the Ethics Committee
of the Universidade Federal de Minas Gerais (n° ETIC
11668613.7.0000.5149), advisory board of CNS.
The isolation and culture of hASCs was performed as
previously described [5]. Briefly, 15 mL of the raw lipoaspi-
rates were washed with phosphate-buffered saline (PBS)
and enzymatically digested with 0.075% collagenase type I
(Life Technologies, USA) in PBS at 37°C for 1 hour. Subse-
quently, the stromal vascular fraction was isolated by cen-
trifugation at 252 g for 10 minutes, and the pellet was
resuspended in basal medium, plated into polystyrene cell
culture flasks (T25; Sarstedt, USA) and incubated at 37°Cin a humidified 5% CO2 atmosphere (Water Jacketed CO2
Incubator; Thermo Scientific, USA). The hASCs were
maintained under two distinct culture conditions: basal
medium with 10% aHS or 10% FBS. After 12 to 28 hours
of incubation, the medium was changed and nonadherent
cells were removed.
The hASCs were maintained at subconfluent levels,
with three weekly medium changes. When the cells
reached 80 to 90% confluence, they were washed with
PBS and treated with 0.05% trypsin-EDTA (Invitrogen,
Canada) for 3 to 5 minutes to detach from the surface of
the culture flask. The resulting suspension was replated
in new cell culture flask. The hASCs were expanded this
way until they were used in the assays. To perform the
assays the cells were harvested with basal medium after
the treatment with trypsin-EDTA, centrifuged and
counted in a Neubauer chamber (HBG, Germany) to
seed the cell number accordingly for each assay.
In vitro cell viability and proliferation
Cell viability and proliferation were assessed at passage 4
by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) assay (Invitrogen) as previously
described [42]. The hASCs were cultured in 24-wells
plate (Sarstedt) with basal medium supplemented with
aHS or FBS at 37°C in a humidified 5% CO2 atmosphere.
At the end of each time point (7, 14, 21, and 28 days)
the medium was removed and 170 μL of the MTT solu-
tion (5 mg/mL) and 210 μL of new basal medium were
added to each well. Two hours later, the formazan crys-
tals were dissolved with 210 μL SDS-10% HCl. After
18 hours, 100 μL solution was transferred to a 96-well
plate (Sarstedt), and the optical density (OD) was mea-
sured at 595 nm using the Anthos 2010 Microplate
Reader Standard (Biochrom, UK) and ADAP Basic soft-
ware (Anthos Labtec, Austria).
In vitro differentiation potential
hASCs were induced to differentiate toward the adipo-
genic, osteogenic, and chondrogenic lineages for 21 days
[5]. For adipogenic differentiation, 1 × 103 cells/cm2 were
cultured in a 6-well plate (Techno Plastic Products AG,
Switzerland) in adipogenic medium with three weekly
medium changes. Oil Red O staining (Thermo Scientific)
was performed following the manufacturer’s instructions
as an indicator of intracellular lipid accumulation. The
cells were washed with PBS and fixed in 10% formalin
for 1 hour. The cells were then washed with 60% isopro-
panol and stained with an Oil-Red O (Thermo Scientific)
solution in 60% isopropanol for 5 minutes, rinsed with
deionized water, and counterstained with hematoxylin
for 1 minute. Osteogenic differentiation was induced by
culturing 2.5 × 103 cells/cm2 in a 24-well plate in osteo-
genic medium with three weekly medium changes.
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as an indicator of extracellular matrix calcification. For
von Kossa staining, the cultures were fixed in 70% etha-
nol, incubated with 5% silver nitrate (Vetec, Brazil) and
exposed to ultraviolet light for 1 hour. Cells were rinsed
with distilled water and 5% sodium thiosulfate (Cinética
Química Ltda) and counterstained with eosin for 40 sec-
onds. Chondrogenic differentiation was induced by cultur-
ing hASCs in a three-dimensional pellet. For pellet
cultures, 5 × 105 cells were centrifuged at 800 g for 5 mi-
nutes in a 15-ml polypropylene conical tube (Sarstedt).
Pellets were then cultured in chondrogenic medium
with media changes once a week. Differentiation was
assessed by embedding the pellets in paraffin, section-
ing them (5 μm sections), and then performing histo-
logical staining with Alcian Blue 8GX (1% in acetic
acid, pH 2.5; Sigma-Aldrich) for 30 minutes, which
stains proteoglycans and glycosaminoglycans, and
counterstaining with hematoxylin for 1 minute.
Flow cytometry analysis
Immunophenotypic analysis of hASCs was performed
at passages 4 and 10. The protocol was adapted from a
previously published study [43]. Briefly, 5 × 105 cells
were incubated with 0.4 μg of each monoclonal primary
antibody for 30 minutes at 4°C. After washing with PBS
to remove unconjugated primary antibodies, the cells
were incubated with Alexa Fluor 488 goat anti-mouse
(Invitrogen) as a secondary antibody for 30 minutes at
4°C. Finally, the cells were washed with PBS and fixed
with 200 μL 1% paraformaldehyde. As a control, hASCs
were also incubated with only the secondary antibody
to assess the background fluorescence. The following
antibodies were used: CD90, CD166, CD45, CD19,
CD105-fluorescein isothiocyanate (FITC), CD44 (HCAM),
CD73-phycoerythrin (all from BD Biosciences, USA),
CD54-FITC (ICAM; Caltag Medsystems, UK), CD34
(Santa Cruz Biotechnology, USA), HLA-ABC-FITC and
HLA-DR-FITC (Abcam, USA). The hASCs were analyzed
with a Guava® easyCyte™ 6-2 L Flow Cytometer (Millipore,
USA) using Incyte acquisition software (Millipore). A
minimum of 15,000 events were acquired for each experi-
mental group. The data were analyzed with FlowJo 7.5.6
software(Treestar, Inc., USA ).
Ki-67 expression - indirect immunofluorescence
hASCs at passage 4 and 10 were cultured at a density of 2 ×
104 cells/cm2 on tissue culture polystyrene coverslips
(2.2 cm× 2.2 cm) in basal medium with aHS or FBS for
24 hours. Subsequently, the cells were analyzed for Ki-67 nu-
clear expression. Briefly, the cells were fixed with 4% parafor-
maldehyde and rinsed with 0.2% Triton-X for 10 minutes.
The cells were blocked for 1 hour at room temperature with
a blocking buffer containing 1% bovine serum albumin and5% goat serum in PBS. After washing with PBS, the samples
were incubated for 2 hours with rabbit monoclonal anti-
human Ki-67 (1:50 dilution; Abcam) and mouse monoclonal
anti-human α-tubulin (1:1,000 dilution; Sigma) primary anti-
bodies. Following a wash with PBS, the samples were incu-
bated with Alexa Fluor 488 goat anti-rabbit and Alexa Fluor
555 goat anti-mouse (Invitrogen) secondary antibodies for
1 hour. The nuclei were stained with 1 mg/mL Hoechst
33258 pentahydrate (Invitrogen) for 20 minutes. The cells
were then visualized by confocal microscopy (Zeiss LSM 5
Live, Germany). The cell nuclei expressing Ki-67 were
counted in 10 different regions of the coverslips using the
Cell counter tool of Image J software (National Institutes of
Health, USA) to determine the number of Ki-67-positive
cells in relation to total cell number in culture, represented as
percentage of Ki-67-positive nuclei in a graph.
Proliferation kinetics
To assess proliferation kinetics, the hASCs were ex-
panded and analyzed at each passage until passage 14. A
density of 4 × 103 cells/cm2 was seeded initially and cul-
tured in T25 culture flask (Sarstedt). Once the cells
reached a subconfluence of 90%, they were counted
using a Neubauer chamber (HBG) and passaged. The
number of population doublings (PD) was calculated
starting at passage 2 because the number of plastic-
adherent cells could first be determined at passage 1. At
each passage, the cells were re-plated at the initial density
of 4 × 103 cells/cm2 in T25 culture flask. If they did not
reach a minimum confluence of 80% after 15 days, the
culture was discontinued. PD was determined using the
following formula: PD = [log10NH – log10NS] ÷ log102,
where NS is the cell number at seeding (4 × 103 cells/cm2)
and NH is the cell number at harvest [20]. To calculate
the cumulative number of population doublings (CPD),
the PD determined for each passage was then added to
the CPD of the previous passage.
In parallel, cell population doubling time (DT) was calcu-
lated at the phase of exponential growth using the follow-
ing formula: DT = (TH – TS) × log102 ÷ log10(NH ÷ NS),
where TS and NS are the time and cell number at seeding,
respectively, and TH and NH are the time and cell number
at harvest, respectively [26].
A growth curve of hASCs cultured at passage 4 was
also generated. Briefly, 2 × 102 cells/cm2 were plated in
T25 cell culture flasks and cultured. At days 3, 5, 7, 9,
and 11, cells from T25 flasks were harvested and
counted with a Neubauer chamber (HBG). The fold ex-
pansion from seeding at day 0 was calculated and com-
pared for both supplements.
Transcription factors expression - immunoblotting
Immunoblotting was performed using standard methods
[44]. In brief, for c-FOS protein evaluation, hASCs at
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and lysed with a lysis buffer (20 mM HEPES, pH 7.0,
10 mM KCl, 2 mM MgCl2, 0.5% NonidetP-40). The
homogenate was incubated on ice for 10 minutes and
homogenized by vortex. Then, the homogenate was cen-
trifuged at 1,500 g for 5 minutes to sediment the nuclei.
The supernatant was then centrifuged at 16,100 g for
20 minutes, and the resulting supernatant consisted of
the non-nuclear fraction. To extract nuclear proteins,
the isolated nuclei pellets were resuspended in NETN
buffer (150 mM NaCl, 1 mM EDTA, 20 mM Tris–HCl,
pH 8.0, 0.5% Nonidet P-40), and nuclear lysates were
collected after centrifugation at 16,100 g for 20 minutes
at 4°C. For c-MYC protein evaluation, the hASCs at pas-
sage 4 and 10 were washed three times with PBS and
harvested by scraping and lysed with NETN buffer. The
homogenate was incubated on ice for 10 minutes and
then centrifuged at 16,100 g for 20 minutes. The result-
ing supernatant consisted of the cell lysate. Protease and
phosphatase inhibitors (Sigma) were added to all buffers.
The immunoblots were performed as described previ-
ously [44]. Protein samples (30 μg) were separated on a
10% gradient SDS-PAGE gel by electrophoresis and
transferred onto a polyvinylidene fluoride membrane
(Millipore). The membranes were blocked with 5% non-
fat milk and incubated with the relevant antibodies:
rabbit anti-human c-FOS (Sigma) and mouse anti-
human Lamin B1 (Abcam) at 1:2,000, rabbit anti-human
c-MYC (Sigma) and rabbit anti-human GAPDH (Santa
Cruz, USA) at 1:500, and rabbit or mouse peroxidase-
conjugated secondary antibody (Sigma) at 1:5,000. Blots
were visualized by enhanced chemiluminescence and
quantitatively analyzed using Image J software.
Real-time quantitative PCR
Quantitative (q)PCR was performed to evaluate the
mRNA levels of the v-myc avian myelocytomatosis viral
oncogene homolog (MYC) gene that encodes the human
c-MYC protein, the cyclin-dependent kinase inhibitor
2A (CDKN2A) gene, also known as p16, and v-erb-b2
avian erythroblastic leukemia viral oncogene homolog 2
(ERBB2). The evaluation of the telomerase reverse tran-
scriptase (TERT) gene was also performed. The gene
expression was assessed in hASCs at passage 4 and 10
(n = 3), using glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) as the reference gene. Total cellular RNA
was extracted using Trizol reagent (Invitrogen), as de-
scribed by the manufacturer. Total samples were
treated with DNase (Promega, USA) according to the
usage information, and the synthesis of cDNA was per-
formed with a RevertAidTM H Minus M-MuLV RT kit
(Fermentas, Lithuania).
The primers used in the qPCR assays were designed
using the Primer3 program, version 0.4.0 [45]. Thesequences of the forward and reverse primers used for
amplification of GAPDH [GenBank: NM_002046.5], TERT
[GenBank: NM_198253.2], MYC [GenBank: NM_002467.4],






5′-AAGCCGCTCCACATACAGTC-3′ (MYC-R′); 5′ -GCCG
ATCCAGGTCATGATGA-3′ (CDKN2A-F′), 5′- ACGGGTC
GGGTGAGAGTG-3′ (CDKN2A-R′); 5′-. GAACTCACCTA
CCTGCCCAC-3′(ERBB2-F′), 5′- GACCTGCCTCACT
TGGTTGT-3′ (ERBB2-R′).
Each qPCR reaction contained 10 μL SYBR Green PCR
Master Mix 2X (Applied Biosystems, UK); 10 ng of cDNA;
each forward and reverse primer at the optimized concen-
trations (0.5 μM of TERT, 0.3 μM of MYC, 0.2 μM of
CDKN2A, 0.2 μM of ERBB2 and 0.5 μM of GAPDH) and
water up to a final volume of 20 μl. The reaction profile
was an initial step of 50°C for 2 minutes and a step of de-
naturation at 95°C for 10 minutes, followed by 45 cycles of
denaturation at 95°C for 15 seconds and combined anneal-
ing and extension at 60°C for 60 seconds. A “no template
control” was made in all the qPCR reactions for each pair
of primers containing all the reagents except cDNA. Each
sample was tested in triplicate. Reaction specificity was con-
firmed with melting curves analysis and agarose gel electro-
phoresis experiments. Standard curves were generated with
series of log dilutions of cDNA to calculate the amplifica-
tion efficiency.
The qPCR reactions were performed using Applied
Biosystems 7500 Fast Real Time PCR System (Applied
Biosystems), and the data were processed by the 7500
Software, version 2.3 (Applied Biosystems).
The calculation of gene expression was performed
using the 2-ΔCt method, where ΔCt = Ct value of target
gene - Ct value of reference gene [46].
Replicative senescence
The expression of pH-dependent senescence-associated
β-galactosidase (SA-β-gal) activity by hASCs was ana-
lyzed at each passage until passage 14 using the SA-β-
gal staining kit (Sigma) as described by the manufacturer
[47,48] and, for hASCs cultured in aHS, they were also
evaluated at passage 15 and 17 for a better analysis.
Briefly, 5 × 103 cell/cm2 were cultured in a 24-well plate
for 24 hours. After this time, the monolayer cultures
were washed twice with PBS, the hASCs were fixed for
6 minutes with fixation buffer (2% formaldehyde/0.2%
glutaraldehyde) at room temperature, washed three
times with PBS and incubated for 4 hours with fresh
SA-β-gal stain solution [5-bromo-4-chloro-3-indolyl P3-
D-galactoside (X-gal), potassium ferrocyanide, potassium
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at 37°C without CO2. The blue-stained cells were then
observed under an optical microscope (Olympus IX70,
Japan) and photographed using the Image Pro Plus 7.01
software. The cells were counted using the Cell counter
tool of Image J to calculate the percentage of cells ex-
pressing β-galactosidase in the culture and the results
were plotted on a graph.Cytogenetic analysis
The karyotyping of hASCs was carried out at passage 4
and 10. When the cells reached 90% confluence, cell div-
ision was halted using Kario Max colcemid solution
(Invitrogen). Subsequently, the cells were harvested by
treatment with 0.05% trypsin-EDTA, resuspended in
hypotonic solution 0.075 M KCl (Merck, Brazil) and
then fixed in a 3:1 methanol acetic acid solution (Merck)
[49]. After spreading the fixed cells on a glass slide, the
cells were subjected to G banding and chromosomal
analysis according to the International System for Hu-
man Cytogenetic Nomenclature [50].In vivo tumorigenesis in mice
The tumorigenicity assay was performed using 8-week-
old Mus musculus nude/nude male mice (n = 3 per
group). The procedure was approved by the Ethics
Committee in Animal Research from the Universidade
Federal de Minas Gerais n° 373/2012 and under local
ethical guidelines. MDA-MB-231 (breast cancer) cells
and FN052 induced pluripotent stem cells (iPS) were
used as a positive control for the assay. The FN052 iPS
were kindly provided by the National Laboratory of
Embryonic Stem Cells, Brazil. As several authors have
reported that MSCs cultivated in vitro in medium sup-
plemented with FBS can be expanded over multiple cell
doublings without tumor or teratoma formation [51] we
decided to eliminate the group of hASCs cultured in
FBS for this assay to reduce the number of animals in-
volved in this study in accordance with the ethical stan-
dards requirements. The procedure was conducted as
described before [52]. Briefly, cells (1 × 106) cultured in
basal medium with 10% aHS at passage 4 were washed
with PBS and then resuspended in PBS with 50% Matri-
gel (BD Biosciences). Then, the cells were injected in the
dorso-lateral area into the subcutaneous space. The ani-
mals were monitored for tumor growth. If a tumor was
visible and palpable, the animals were euthanized. The
tumor was removed, documented photographically and
measured with digital caliper. The tumor was fixed for
60 minutes in 10% formalin, routinely processed, embed-
ded in paraffin, and cut into 6 μm sections. The tumor
sections were assessed by histological staining with
hematoxylin and eosin.Statistical analysis
All experiments were done in triplicate with the samples
of the 10 different donors. The graphs and the statistical
analyses were performed using Graph Pad Prism 5.0.
The values are presented as the mean ± standard error
of the mean. For the data from each type of experiment,
the most suitable statistical analysis was performed:
student’s t‐test and analysis of variance followed by
Bonferroni’s or Tukey’s Multiple Comparison post-tests.
Differences were considered significant at P < 0.05.
Results
Isolation and culture of human adipose tissue-derived
stem cells
The isolation of hASCs using both culture medium
supplemented with aHS and FBS was successful. The
adherent cells formed several colonies and had a
fibroblast-like morphology. However, the hASCs cul-
tured in aHS were smaller and denser than those cul-
tured in FBS (Figure 1A,B). The hASCs also adhered
less to the culture plastic surface, as the time required
for the cells to detach from the plastic surface during
trypsinization was approximately 3 minutes in basal
medium with aHS and 5 minutes with FBS. Moreover,
when the hASCs cultured in aHS reached confluence
they had a tendency to cluster.
In vitro cell viability and proliferation
The hASCs in both types of medium supplements were
able to metabolize the MTT into formazan crystals and
the OD value enhanced from 7 to 28 days, which dem-
onstrated high viability and proliferation (Figure 1C).
When the hASCs were cultured in basal medium with
aHS, they exhibited significantly higher OD compared to
cultures of hASCs in basal medium with FBS, indicating
enhanced proliferation.
In vitro differentiation potential
This assay demonstrated that aHS did not adversely
affect the differentiation capacity of hASCs. Intracellu-
lar lipid vacuoles were visible by light microscopy in-
spection of cells under adipogenic induction with aHS
(Figure 1D) or FBS (Figure 1E). Osteogenic differenti-
ation was confirmed by the deposition of a mineralized
matrix in aHS cultures (Figure 1F) and FBS cultures
(Figure 1G). Chondrogenic differentiation was evident
in both types of culture conditions, as shown by glycos-
aminoglycan staining (Figure 1H,I).
Flow cytometry analysis
Cell size and granularity were measured during the flow
cytometry analyses using the forward- and side-scatter
settings, and the results showed that the hASCs cultured
in basal medium with aHS (Figure 2A) were smaller and
Figure 1 Characteristics of human adipose tissue-derived stem cells from a representative donor at passage 4. (A,B) Fibroblast-like morphology
of human adipose tissue-derived stem cells (hASCs) cultured in basal medium supplemented with (A) allogeneic human serum (aHS) and (B) fetal
bovine serum (FBS); scale bar 500 μm. (C) Viability and proliferation of hASCs evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay performed 7, 14, 21 and 28 days after culture in both culture medium supplements. The results are based on optical density
at 595 nm and represent the viability and proliferation of hASCs in basal medium supplemented with aHS and FBS. The results represent the
mean ± SEM. Statistical analysis by analysis of variance and Bonferroni’s post-test was performed. *P < 0.05, versus FBS . (D-I) Multipotentiality of
hASCs cultured in basal medium with aHS (left panels) and FBS (right panels). Oil red O staining showed consistent adipogenic differentiation of
hASCs cultured in basal medium with (D) aHS and (E) FBS; scale bar 150 μm. von Kossa staining confirmed osteogenic differentiation of hASCs
cultured in basal medium with (F) aHS and (G) FBS; scale bar 50 μm. Alcian blue staining verified chondrogenic differentiation of hASCs cultured
in basal medium with (H) aHS and (I) FBS; scale bar 150 μm.
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medium with FBS (Figure 2B). The levels of surface
marker expression did not change significantly between the
passages or culture medium supplements used. The immu-
nophenotypic profile of hASCs cultured in aHS and FBS in-
dicated that more than 90% of the hASC populations
expressed MSC markers CD105, CD166, CD90, CD73 and
surface adhesion molecules CD44 and CD54, and the cell
cultures lacked the expression of HSC: hematopoietic stem
cell; markers CD45, CD34, CD19 and HLA-DR (<2% posi-
tive). Moreover HLA-ABC was expressed by approxi-
mately 100% of hASCs in both culture conditions and
different passages. These results suggest that hASCs
cultured in aHS- (Figure 2C) or FBS-supplemented
(Figure 2D) medium share a highly similar phenotype.
Ki-67 expression - indirect immunofluorescence
The nuclear expression of Ki-67 protein was evidenced
by green nuclear fluorescence, and the red fluorescence
indicated the shape of the hASCs (α-tubulin expression;
Figure 3A). The estimated percentage of Ki-67-positive
cells in culture showed that approximately 81.64% of
hASCs cultured in basal medium with aHS at passage 4
were positive for Ki-67, and this number significantly de-
creased to 37.77% at passage 10. Nevertheless, hASCs
cultured in basal medium with FBS presented significantlylower expression of Ki-67, with approximately 8.25% Ki-
67-positive cells at passage 4 and only 6.54% at passage
10, but no significant difference was observed between the
passages (Figure 3B).Proliferation kinetics
CPD were higher for the cells cultured in basal medium
with aHS compared with FBS (Figure 4A). aHS exerted a
strong and continuous proliferative effect on hASC
growth that was observed up to passage 14. In contrast,
hASCs cultivated in FBS exhibited slow but continuous
proliferation that was observed only until passage 10.
After passage 8, the hASCs cultured in FBS took more
than 2 weeks to reach confluence.
For each of the donors, the DT was consistently
shorter in hASCs cultured in aHS (24.3 ± 1.9 hours)
compared to hASCs in FBS (122.1 ± 1.8 hours).
To better evaluate the period of highest proliferation,
growth curves were generated. Notably, the growth
curve of hASCs cultured in aHS showed rapid growth
starting at day 7, while the accelerated growth of hASCs
in FBS did not start until day 9. After day 9, the hASC
cultures in aHS had already reached total confluence in
the flask and may have stopped proliferating, while the
FBS cultures were still proliferating (Figure 4B).
Figure 2 Immunophenotypic analysis of human adipose tissue-derived stem cells. Flow cytometry analysis, where the dot plots represent the cell
size and granularity of human adipose tissue-derived stem cells (hASCs) cultured in basal medium with (A) allogeneic human serum (aHS) and
(B) fetal bovine serum (FBS). Expression of the selected mesenchymal stem cell, hematopoietic and human leukocyte antigens markers are depicted
with representative histograms for (A) aHS cultures and (B) FBS cultures. The gray peak indicates the isotype-matched monoclonal antibody control.
The black peak indicates positively stained cells. The cell populations expressed CD166, CD105, CD90, CD73, CD44, CD54 and HLA-ABC, and
did not express CD45, CD34, CD19 and HLA-DR. (C-D) Bar graphs represent the quantitative analysis of the hASC expression pattern of markers
in basal medium supplemented with (C) aHS and (D) FBS.
Paula et al. Stem Cell Research & Therapy  (2015) 6:76 Page 8 of 19Transcription factors expression - immunoblotting
There was no significant difference in c-FOS protein
expression level in hASCs cultured in aHS compared to
its expression in FBS cultures at passage 4 (Figure 5A)
and no significant difference was observed within thegroups considering the passages 4 and 10 (data not
shown). Nevertheless, a significant difference in c-MYC
protein expression level was observed in hASCs cul-
tured in aHS compared to its expression in FBS cul-
tures at both passages (passages 4 and 10), with higher
Figure 3 (See legend on next page.)
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Figure 3 Ki-67 nuclear protein expression in human adipose tissue-derived stem cells. (A) Confocal images of the expression of Ki-67 (green) in
nuclei and α-tubulin (red), showing the cell shape of human adipose tissue-derived stem cells (hASCs) cultivated in basal medium supplemented
with allogeneic human serum (aHS) and fetal bovine serum (FBS) at passages 4 (P4) and 10 (P10). Cell nuclei were stained with Hoechst (blue);
scale bar 20 μm. (B) Percentage of Ki-67-positive cells/total cells expressed as the mean ± SEM. Analysis of variance and Tukey’s multiple comparison
test was performed. *P < 0.05, versus FBS; #P < 0.05, versus P4.
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aHS. No significant difference was observed within the
groups considering the different passages (Figure 5B).
Real-time quantitative PCR
There was no significant difference in MYC mRNA
expression level (2-ΔCt) in hASCs cultured in aHS at
passage 4 (0.0326 ± 0.0060) compared to its expression
in FBS cultures at the same passage (0.0253 ± 0.0049).
However, MYC expression significantly decreased
(0.0134 ± 0.0003) in aHS cultures and (0.0108 ± 0.0024) in
FBS cultures at passage 10 when compared to passage 4,
but no significant difference was observed between the
groups at passage 10 (Figure 6A).
Low expression of TERT mRNA by hASCs was ob-
served in both basal medium supplements (Figure 6B).
There was a significant difference in TERT expression
levels in hASCs cultured in aHS at passage 4 (0.9803 ×
10−4 ± 0.2870 × 10−4) compared to its expression in FBS
cultures at the same passage (0.1824 × 10−4 ± 0.10657 ×
10−4). However, no significant difference was observed
comparing aHS cultures (0.1384 × 10−4 ± 0.07541 × 10−4)
with FBS cultures (0.06259 × 10−4 ± 0.03165 × 10−4) at
passage 10. Moreover, there was a significant difference
in TERT expression comparing passage 4 with passage
10 considering both media (P < 0.05).
Low expression of CDKN2A mRNA by hASCs was ob-
served in cells cultured in both basal medium supple-
ments (Figure 6C). There was a significant difference in
CDKN2A mRNA expression level in hASCs cultured in
aHS at passage 4 (1.0107 × 10−3 ± 0.0479 × 10−3) com-
pared to its expression in FBS cultures at the same
passage (2.7453 × 10−3 ± 0.3577 × 10−3). However, no sig-
nificant difference was observed comparing aHS cultures
(0.4415 × 10−3 ± 0.0232 × 10−3) with FBS cultures (0.2336 ×
10−3 ± 0.0405 × 10−3) at passage 10. Moreover, there was a
significant difference in CDKN2A expression comparing
passage 4 with passage 10 considering both media (aHS
and FBS supplements; P < 0.05).
Regarding ERBB2, low mRNA expression was ob-
served in cells cultured in both basal medium supple-
ments (Figure 6D). There was a significant difference in
ERBB2 mRNA expression levels in hASCs cultured in
aHS at passage 4 (0.25000 × 10−3 ± 0.01523 × 10−3) and
FBS cultures at the same passage (0.57743 × 10−3 ±
0.09114 × 10−3). However, ERBB2 expression signifi-
cantly increased (1.31040 × 10−3 ± 0.091670 × 10−3) inFBS cultures at passage 10 when compared to passage
4, while no significant difference was observed compar-
ing aHS cultures at passage 4 and (0.25168 × 10−3 ±
0.013670 × 10−3) passage 10. Moreover, there was a sig-
nificant difference in ERBB2 expression comparing aHS
cultures and FBS cultures at passage 10 (P < 0.05).
Replicative senescence
Senescent cells expressed β-gal that was detected in sin-
gle cells by X-gal staining. Moreover, the senescent cells
presented changes in their morphology due to cell en-
largement and the presence of more cytoplasmic vacu-
oles (Figure 7A,B). Only 1.33% of cells in aHS were
positive for β-gal at passage 10 (Figure 7C). However,
the hASCs cultivated in FBS expressed β-gal earlier than
the cells in aHS, with 25.63% of cells being senescent at
P10 (Figure 7D), which is a significant level of senes-
cence compared with the previous passages. The per-
centage of senescent cells in hASCs cultivated in aHS
was significant increased only at passage 17 compared
with the previous passages - at this passage, 27% of the
cells in culture were senescent. This result indicates a
slower senescence process in hASCs cultured in aHS
than in FBS (Figure 7E).
Cytogenetic analysis
Karyotype analyses revealed karyotype 46, XX for cells
cultivated in both medium supplements, confirming a
normal diploid karyotype and demonstrating that no
chromosomal alterations had occurred in both passages
evaluated (Figure 8).
In vivo tumorigenesis in mice
The hASCs cultivated in basal medium with aHS were
not able to generate tumors in the animals within
24 weeks (Figure 9A). Histological analysis did not reveal
any cell or tissue differences other than those expected
for subcutaneous tissue, between dermis and muscular
tissue (Figure 9B). The animals injected with positive
control MDA-MB-231 cells formed malignant tumors
after 5 weeks. The tumors presented approximate di-
mensions of 8.13 mm × 7.02 mm × 5.46 mm. The histo-
logical analysis revealed the following features: solid
tumor with pleomorphism, mitotic activity and well-
delimited tumors (Figure 9C). Moreover, necrosis in the
inner area was observed in some tumors. Animals
injected with the other positive control FN052 iPS cells
Figure 4 Proliferation kinetics of human adipose tissue-derived stem
cells cultured in basal medium supplemented with allogeneic human
serum and fetal bovine serum. (A) Mean cumulative population
doublings measured and expressed as a function of passage number
for allogeneic human serum (aHS; black bars) and fetal bovine serum
(FBS; white bars). The results represent the mean ± SEM. Analaysis of
variance (ANOVA) with Bonferroni's post-test was performed. P < 0.05,
comparing the condition of basal medium with aHS to basal medium
with FBS at all passages and for comparisons between all passages
for the condition of basal medium supplemented with aHS. For
comparisons between all passages for the condition of basal medium
supplemented with FBS: *P < 0.05 for the P1 × P3 comparison; #P < 0.05
for the P3 × P5 comparison; +P < 0.05 for the P5 × P6 comparison;
ɸP < 0.05 for the P6 × P8 comparison. (B) Growth curve assessing the
proliferation kinetics of human adipose tissue-derived stem cells
cultivated in basal medium supplemented with aHS and FBS at days 3,
5, 9, and 11. ANOVA with Bonferroni's post-test was performed. *P < 0.05,
comparing hASCs cultured in basal medium with aHS to FBS at days
7, 9 and 11; #P < 0.05, comparing the growth between days 7 and 9 in
basal medium supplemented with aHS; ɸP < 0.05, for the comparison
between days 9 and 11 in basal medium supplemented with FBS.
Paula et al. Stem Cell Research & Therapy  (2015) 6:76 Page 11 of 19formed one clearly identifiable tumor in the locale of the
injection after 12 weeks. The tumors presented approxi-
mate dimensions of 14.16 mm × 15.86 mm × 8.04 mm
(Figure 9D). The tumors were very heterogeneous, and
histological analysis revealed tissues from all three germ
layers, featuring teratoma. Representative tissue sections
stained with hematoxylin and eosin indicated transi-
tional epithelium (endoderm-like tissue; Figure 9E),
neural ectoderm (ectoderm-like tissue; Figure 9F) and
skeletal muscle (mesoderm-like tissue; Figure 9G).
Discussion
There are several clinical trials evaluating hASCs
[6,11-14]. Current limitations of using MSCs in clinical
applications include providing a sufficient number of
cells in a timely manner. Furthermore, it is necessary to
maintain cell viability and differentiation capacity. There
are a considerable number of ex vivo MSCs expansion
protocols, and FBS has been used to culture diverse cell
types for many years.
The serum is important to supplement the cell culture
medium because it is a complex mixture of large num-
ber of components such as: (1) hormonal factors; (2)
transport proteins carrying hormones, minerals and
trace elements and lipids; (3) attachment and spreading
factors; and (4) stabilizing and detoxifying factors [18].
However, the serum requirements hinder clinical appli-
cations. The FBS has several disadvantages: it is an ill-
defined medium supplement, and thus an ambiguous
factor in MSC culture due to by batch-to-batch variabil-
ity. Moreover, FBS contains xenogeneic proteins that are
internalized or attached on the surfaces of cells [20-22],
and can generate immune responses in some patients
[53]. Also, it can transmit viruses, prions, bacterias,
mycoplasma and endotoxins [23,24].
Therefore, the substitution of FBS with a supplement
free of xenogeneic proteins is essential to ensure cell
manipulation in accordance with GMP guidelines. De-
veloping an efficient, serum-free and chemically defined
cell culture condition is an important issue. Different
studies have attempted to replace FBS with human-
derived alternatives [25-30,54-56] or serum-free defined
media [31-35,57,58].
The serum-free defined media are comprised of syn-
thetic supplements that replace serum and reduce vari-
ability, which offer the most promising alternative.
Studies show that MSC culture in serum-free media is
feasible. However, the MSCs seem to fail to maintain a
similar pattern of expansion observed in serum supple-
mented cultures [57,58].
To date, there is much, but some contradictory, infor-
mation about the influence of the different types of hu-
man substitutes on hASC proliferation and differentiation.
Autologous human serum a priori is the best replacement
Figure 5 Transcription factors expression of human adipose tissue-derived stem cells cultured in basal medium supplemented with allogeneic
human serum and fetal bovine serum. (A) Representative immunoblot of c-FOS transcription factor (60 kDa) expression from nuclear fractions of
human adipose tissue-derived stem cells (hASCs) at passage 4. Densitometric analyses showed no significant difference in the c-FOS expression in
hASCs in both culture medium supplements. Lamin B (60 kDa) was used as a purity control for the nuclear fractions (n, nuclear; nn, non-nuclear).
The results were plotted and Student’s t‐test was performed. No significant differences were detected (statistical significance was set at P < 0.05,
two‐tailed). (B) Representative immunoblot for c-MYC transcription factor (120 kDa) expression in total extracts of hASCs at passages 4 (P4) and
10 (P10). Densitometric analyses showed that c-MYC in hASCs cultured in basal medium supplemented with allogeneic human serum (aHS) is
expressed more than in fetal bovine serum (FBS) in both passages evaluated. GAPDH (37 kDa) was used as a purity control for the total extracts.
Bar graph summary showing that hASCs cultured in basal medium with aHS had increased expression of c-MYC compared to cells cultured in
basal medium supplemented with FBS. Analysis of variance and Tukey's multiple comparison test was performed. *P < 0.05.
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plicability of autologous human serum for large-scale
MSC production [28]. Moreover, studies suggest that nat-
ural clotted serum has a better effect in stimulating cell
proliferation than plasma, which could be due to the re-
lease of certain polypeptides and growth factors from the
activated platelets during the clotting process [18,59].
Thus, in this study, we proposed the use of aHS pro-
duced from all types of blood groups, which could be
available in large amounts for manufacturing and could
easily be controlled for quality according to blood bank-
ing standards to meet GMP regulations. Additionally, to
reduce the variability imposed by different compositions
between the serum from different donors, each batch of
aHS was constituted of serum from at least 20 different
donors (five of each blood type: A, B, AB and O). The
choice to use aHS is justified because it has previously
been shown that the ABO antigens, as well as other pro-
tein and carbohydrate-based antigens, are not detectable
on the surface of MSCs, and these cells do not adsorb
immunogenic ABO antigens from culture media con-
taining human substitutes [60,61].
The isolations and expansion of hASCs using medium
with aHS were successful, and their morphologic charac-
teristics were comparable to hASCs expanded in FBS.
The hASCs were fibroblast-like cells, adherent andformed several colonies. The smaller size, reduced
granularity, decreased adherence, much denser growth
and tendency to cluster at confluence observed for the
hASCs cultured in aHS were previously described in a
study by our group [40]. These observations also agree
with another published study [27] that showed similar
characteristics for hASCs cultured in human AB serum
and PRP: platelet-rich plasma. Furthermore, whole-
genome analysis of hASCs cultured in human AB serum
detected lower expression of adhesion and extracellular
matrix-associated molecules, supporting the reduced cell
adhesion to plastic surfaces during culture with these
supplements [62]. However, in this study, the evaluation
of the expression of surface adhesion molecules CD44
and CD54 showed that the hASCs did not present lower
expression of these proteins when they are cultured in
aHS. The cells cultured in aHS expressed approximately
95.50% of CD54 and 98.40% of CD44, while the cells
cultured in FBS expressed approximately 94.56% of
CD54 and 97.40% of CD44.
The metabolic activity-based assay (MTT) was per-
formed at various time points to determine the cell via-
bility and proliferation when cultured in both types of
culture medium supplements, aHS and FBS. MTT re-
sults are directly proportional to the number of living
cells and they revealed that hASCs cultured in medium
Figure 6 Gene expression of human adipose tissue-derived stem cells cultured in basal medium supplemented with allogeneic human serum
and fetal bovine serum. Real-time quantitative PCR analyses showing the expression of (A) MYC, (B) TERT (C) CDKN2A and (D) ERBB2 in hASCs at
passages 4 (P4) and 10 (P10). The gene expression was calculated by the 2-ΔCt method and GAPDH was used to normalize the data. Analysis of
variance and Tukey’s multiple comparison test were performed (n = 3). *P < 0.05, comparing the gene expression of human adipose tissue-derived
stem cells (hASCs) cultivated in allogeneic human serum (aHS) versus fetal bovine serum (FBS) at passage 4; #P < 0.05, comparing the gene expression
of hASCs cultivated in aHS at passage 4 and passage 10; ΨP < 0.05, comparing the gene expression of hASCs cultivated in FBS at passage 4
and passage 10; ΔP < 0.05, comparing the gene expression of hASCs cultivated in aHS versus FBS at passage 10.
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tion compared to cells cultivated in FBS. Also, the cells
cultured in medium supplemented with aHS differenti-
ated into adipogenic, osteogenic and chondrogenic line-
ages as well as the hASCs cultured in basal medium
supplemented with FBS.
Immunophenotypic characterization confirmed the
smaller size and lower granularity of hASCs cultivated in
aHS compared to FBS. Moreover, no significant differ-
ence in surface marker expression were revealed be-
tween aHS and FBS culture conditions and between the
passages evaluated. The majority of hASCs cultivated in
both culture supplements were positive for MSC
markers (>90%) and had low expression of HSC markers
(<2%), which confirms results reported for hASCs cul-
tured with other human supplements [27,28,40,62].
Thus, hASCs cultured in aHS as in FBS were: (1) plas-
tic adherent; (2) viable; (3) expressed MSC-specific sur-
face antigens and lacked expression of HSC markers;
and (4) were able to differentiate in multiple lineages
under standard in vitro differentiating conditions. This isin accordance with the minimal criteria for defining
MSCs [3] and hASCs [10] stated and accepted by the
International Federation for Adipose Therapeutics and
Science and the International Society for Cellular
Therapy.
Additionally, because hASCs cultured in basal medium
with aHS were denser than with FBS, we evaluated Ki-
67 cell expression. This marker is excellent for determin-
ing the proliferating fraction of a given cell population
because Ki-67 is present in normal cells during all active
phases of the cell cycle (G1, S, G2, and mitosis) but it is
absent from resting cells (G0) [63]. The results from this
analysis confirmed the visual observations of cultures in
aHS, as a significantly higher fraction of Ki-67-positive
hASCs were found in aHS cultures compared to FBS
cultures at passage 4. However, Ki-67-positive cell frac-
tions in aHS cultures decreased at P10 but still remained
higher than in FBS cultures.
While this assessment of the proliferating fraction pro-
vided information about the state of the cells, it did not
provide any information about the rate of proliferation.
Figure 7 Senescence-associated β-galactosidase expression of human adipose tissue-derived stem cells. (A-B) Single cell senescence-associated
β-galactosidase (SA-β-gal) staining showing the formation of a blue precipitate in senescent cells (scale bar 50 μm). Representative images of
human adipose tissue-derived stem cells (hASCs) cultivated in (C) allogeneic human serum (aHS) and (D) fetal bovine serum (FBS) at passage 10
showing earlier β-gal expression by hASCs cultivated in medium with FBS (scale bar 100 μm). (E) Percentage of β-gal-positive cells/total cells at
each passage evaluated, expressed as the mean ± SEM. Analysis of variance with Bonferroni’s post-test was performed. *P < 0.05, comparing the
condition of basal medium with aHS to basal medium with FBS at each passage after passage 8. #P < 0.05, indicates the passage at which the
percentage of senescent cells in the same culture condition were significantly increased.
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The CPD of hASCs was significantly higher for aHS cul-
tures compared to FBS cultures, and CPD trend
remained constant throughout passaging. The CPD of
cells in basal medium with FBS were assessed until pas-
sage 10 because, after passage 8, the cells took more
than 15 days to reach confluence. Most likely, this re-
duced proliferation occurred because hASCs cultured inFBS undergo senescence starting around passage 8, as
we have shown and will discuss later. Growth curve ana-
lysis allowed us to observe that cells in aHS proliferate
faster than cells in FBS at early passages. Moreover, the
DT of hASCs cultured in basal medium with aHS was
approximately five times shorter than the cells in basal
medium with FBS. This proliferation kinetic observed
for aHS cultures is clinically relevant and makes aHS an
Figure 8 Cytogenetic analysis of human adipose tissue-derived stem cells cultured in basal medium supplemented with allogeneic human serum
and fetal bovine serum. Karyotype analysis of human adipose tissue-derived stem cells (hASCs) showed that normal diploid karyotype was maintained
after culturing hASCs in basal medium supplemented with (A) allogeneic human serum (aHS) and (B) fetal bovine serum (FBS), with no abnormal
nuclear pattern being observed during long-term culture. The representative karyotypes shown are from hASCs at passage 10.
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required for transplantation could be obtained in a
shorter period of time.
Several studies have reported that MSCs cultured
in vitro can be expanded over multiple cell doublings
without loss of differentiation potential. Nevertheless,
long-term cultured MSCs can develop chromosomal ab-
normalities with [64] or without evidence of malignant
transformation [51]. Recently, further studies hypothe-
sized that a minimal HT1080 cell lineage contaminationFigure 9 In vivo tumorigenesis. (A) Human adipose tissue-derived stem ce
human serum (aHS) were injected into the dorso-lateral subcutaneous regi
of cell transplantation showed normal skin layers (scale bar 150 μm). (C) Hi
pleomorphism, mitotic activity and well-delimited tumor (scale bar 30 μm)
12 weeks of transplantation. These tumors involved (E) transitional epitheli
(ectoderm-like tissue; scale bar 50 μm), and (G) skeletal muscle (mesoderm
hematoxylin and eosin. Asterisks indicate the dorso-lateral subcutaneous recould have been present in human MSC cell cultures
since the first weeks, and remained undetectable for
months until human MSC advanced senescence mani-
fests [65,66] justifying the malignant transformation of
human MSCs observed by other studies [64]. Although
the majority of human MSC cultures seem to remain
stable, the number of expanded cells is linked to the
growth rate, and a high proliferative rate may potentiate
risk of cytogenetic abnormalities and increase the risks
of promoting tumorigenicity in human MSCs, aslls (hASCs) cultivated in basal medium supplemented with allogeneic
on of nude mice and did not form tumors. (B) Histology of the regions
stology of tumor formed by transplantation of MDA-MB-231 revealed
. (D) The same numbers of FN052 iPS cells formed teratoma after
um (endoderm-like tissue; scale bar 150 μm), (F) neural ectoderm
-like tissue; scale bar 150 μm), as shown by histological staining with
gion of cell transplantation.
Paula et al. Stem Cell Research & Therapy  (2015) 6:76 Page 16 of 19presented in the report of the conclusions of the meet-
ing with European experts in the field of MSCs [67]. It
appears that the majority of cell abnormalities lead to
senescence, but it is difficult to exclude the risk of cell
transformation. The occurrence of genetic aberrations
appears to be related mainly to the manufacturing
process rather than to the patient-derived factors [67],
but some authors affirm that the susceptibility to malig-
nant transformation can be strictly connected with the
origin of the tissue [37,51]. Therefore, it is important to
identify and define ideal culture conditions, which avoid
the occurrence of chromosomal abnormalities.
In this context, the most important question remains
whether this proliferative rate observed in hASCs cul-
tured in basal medium supplemented with aHS is associ-
ated with cell transformation. To the best of our
knowledge, there is not yet evidence in the current lit-
erature that human serum may constitute a suitable and
safe replacement for FBS for culture of hASCs. There-
fore, this is the first study that investigated the prolifera-
tive effects of aHS on hASCs and goes further by
carefully evaluating any evidence of spontaneous malig-
nant cell transformation.
Based on the rapid proliferation observed with aHS cul-
ture supplementation, we evaluated the expression of the
transcriptional factors c-FOS and c-MYC, which are
known to transmit proliferative signals and to regulate
growth and apoptosis [68,69]. Nevertheless, their dysregu-
lated expression is common in human malignancy [70-72].
The levels of c-FOS expression were not affected in
the hASCs cultured in both culture medium supple-
ments. However, the c-MYC expression levels in the
hASCs cultivated in aHS were higher than in FBS in
both passages evaluated (passage 4 and 10). As a study
on murine cells has demonstrated a strong association
between overexpression of c-MYC and tumorigenesis
[36], this higher expression of c-MYC could lead to
spontaneous transformation of hASCs. Nevertheless, the
qPCR analysis of MYC gene expression revealed similar
levels of expression of MYC in hASCs cultured in the
presence of aHS and FBS at passages 4 and 10. More-
over, MYC expression decreased in hASCs cultured in
both media at passage 10 compared to passage 4.
Rabbitts and colleagues [73] showed that MYC mRNA
is present, at equivalent levels, at all times in the cell
cycle. Moreover, the MYC gene (which is capable of be-
ing post-transcriptionally modulated) is activated in the
G0 to G1 by external stimuli (for example, growth fac-
tors). An analysis of the c-MYC in vivo shows that de
novo synthesis occurs in G1 and G2, with a protein turn-
over half-life of approximately 20 to 30 minutes in both
phases. Furthermore, the level of c-MYC rapidly in-
creases in the cell population when they re-initiate the
cell cycle, thereafter decreasing as the cultures reachesquiescence [73,74]. Thus, the precise mechanism of how
this c-MYC protein expression is stimulated by aHS in
hASCs remains to be established, but it is possible that
c-MYC is a proliferative signal involved in the cell prolif-
eration pattern observed.
Constitutive expression of TERT, the gene that con-
trols the length of telomeric ends, has been shown to
prevent senescence, increase proliferation and maintain
differentiation ability in MSCs [75,76]. Moreover, c-
MYC has been described to activate the transcription of
TERT, which may contribute to sustaining the prolifera-
tion of tumor cells along the cell cycle [74]. Therefore,
we evaluated the TERT expression in hASCs cultured
in vitro. We detected a low level of TERT expression in
hASCs cultured in both types of supplement, which
helps to eliminate the possibility of spontaneous
immortalization of the hASCs in aHS. Our results cor-
roborate other studies showing that MSCs usually have a
low level of telomerase activity [26,75].
Prior research has proven that downregulation of the
tumor suppressor gene CDKN2A (encodes p16 protein)
is involved in transformation of MSCs [77,78] and with
several cancers [79] and is a valuable marker that assists
in the identification of tumorigenic cells [80]. At passage
4, the hASCs cultured in aHS had lower expression of
CDKN2A compared with FBS cultures. Nevertheless, no
significant difference was observed between aHS cul-
tures and FBS cultures at passage 10.
We also evaluated the proto-oncogene ERBB2 expres-
sion, also called HER2, that encodes the human epider-
mal growth factor receptor 2, which is a transmembrane
receptor tyrosine kinase. Its oncogenic activation results
in its protein overexpression and subsequent abnormal
cell signaling, contributing to cancer progression. The
overexpression of ERBB2 has been reported to be associ-
ated with different types of malignant tumors in several
studies [81-84]. Fortunately, our results showed that the
hASCs cultured in both culture supplements presented a
low expression of ERBB2.
Replicative senescence is associated with the loss of
telomeric DNA in each cell division due to incomplete
replication of the telomeric ends [75]. As we discussed
earlier, the hASCs had low gene expression of human
TERT. Thus, it was expected that the cells underwent
replicative senescence. Our results showed that the
hASCs cultivated in basal medium with FBS could be
cultivated until passage 8 without any significant senes-
cence, corroborating a previous study [48] in which sen-
escence was found to occur after a CPD ranging from 6
to 16. In contrast, the cells in basal medium with aHS
underwent slower senescence and could be cultured
until passage 17 without significant senescence. Thus,
we can conclude that the pace of senescence is affected
by culture conditions. In both cell cultures positive for
Paula et al. Stem Cell Research & Therapy  (2015) 6:76 Page 17 of 19SA-β-gal, the cells decreased proliferation after they
began to undergo senescence. This result may indicate a
purposeful program of cell senescence that is triggered
irrespective of the culture supplement to protect the
cells from accumulating DNA mutations after cell divi-
sions, which could become malignant cells [48].
Importantly, to exclude cells containing abnormalities
in aHS cultures, we performed a karyotype analysis
which confirmed that no chromosomal alterations had
occurred with the hASCs, as numerical and structurally
normal karyotypes were observed. This result indicates
that the genomic stability of the cells cultivated in aHS
was maintained despite their high proliferation.
Despite their proliferative potential, differentiation
capacity, and c-MYC expression, the hASCs cultivated
in basal medium with aHS did not form tumors in vivo,
as expected for MSCs. Malignant tumors and teratomas
were observed only in the control groups, MDA-MB-
231 and iPS, respectively. Teratoma - non-malignant
tumor-like formations containing tissues belonging to all
three germ layers known as a sine qua non characteristic
of pluripotent stem cells- was observed only for the iPS
control group [52].
In addition to the risk posed by the use of FBS in the
ex vivo expansion of hASCs for clinical purposes, spon-
taneous malignant transformation in vitro is another po-
tential risk [17]. Some groups have reported that human
and murine MSCs ex vivo expanded in medium supple-
mented with FBS become malignant transformed cells
[36,78] exhibiting an increased proliferation rate, altered
morphology, c-MYC overexpression and high telomerase
activity; thus, the cells can escape from senescence and
present cytogenetic abnormalities and form tumors
when injected into immunodeficient mice [17,36,78]. On
the contrary, our results showed that hASCs cultivated
in basal medium with aHS had increased proliferation,
probably due the increased c-MYC expression, but this
proliferation and c-MYC levels showed no association
with the TERT expression, leading to normal karyotypes.
Despite a later senescence compared to FBS cultures,
the hASCs cultured in medium with aHS were not able
to bypass senescence; moreover, no tumor was generated
by these cells. So the results together excluded the possi-
bility of spontaneous immortalization of hASCs. This
complete characterization is highly important consider-
ing the xeno-free approach proposed to culture hASCs
and to ensure a quality and safety standard acceptable
for use in clinical applications.
Conclusions
In conclusion, the results demonstrate that aHS could
be easily produced as an off-the-shelf animal-free sup-
plement for the culture of hASCs intended to be used in
therapy. Notably, aHS provides a high proliferation rate,which can be attributed to c-MYC protein overexpres-
sion in hASCs in this medium compared with medium
supplemented with FBS. This higher proliferation of
hASCs allows the required cell number to be reached in
a short period of time, maintaining phenotypic, func-
tional and genetic stability of the cells throughout long-
term culture. This complete characterization ensures
that no malignant transformation of hASCs is induced
by aHS, and this culture condition supports a safe and
effective transplantation into the patient, which is a step
forward towards achieving the best GMP criteria.
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